The Dahlia Center Stem Cell Investigation

Written by 
Published on:
November 18, 2026
Updated on:
November 18, 2026

Regenerative medicine clinics often market stem cell treatments as potential options for patients facing serious or chronic medical conditions. Promotional materials may feature patient testimonials and claims involving diseases for which conventional medicine offers limited options. Such claims should be scrutinized.

A July 15, 2021, letter from the U.S. Food and Drug Administration (FDA) to The Dahlia Center, LLC, an Ohio-based clinic, brought attention to the regulatory questions surrounding these practices. The agency's review of the clinic's website and social media marketing identified representations involving umbilical cord-derived cellular products and their proposed use for numerous medical conditions.

Call our attorneys if you or a loved one has paid for stem cell treatments that may have been falsely marketed. The Lyon Firm investigates potentially misleading healthcare advertising and consumer protection concerns involving regenerative medicine providers.

FDA Questions Claims Involving Multiple Medical Conditions

The FDA's correspondence described promotional statements on The Dahlia Center's website and Facebook page. According to the agency, the clinic marketed umbilical cord-derived products for conditions including leukemia, prostate cancer, diabetes, Parkinson's disease, Alzheimer's disease, multiple sclerosis, lupus, and congestive heart failure.

The agency also referenced videos featuring accounts of patients experiencing improvements following treatment. These included descriptions of patients with Parkinson's disease, cerebral palsy, and chronic obstructive pulmonary disease. The FDA explained that the products appeared to be human cells, tissues, or cellular and tissue-based products subject to federal regulatory requirements.

Importantly, the correspondence to The Dahlia Center in Ohio was an FDA untitled letter, rather than a formal warning letter. The agency expressed concerns about the products' regulatory classification, intended uses, and the absence of an applicable biologics license or investigational new drug authorization identified in its review.

Misleading Healthcare Advertising and Consumer Protection

The FDA attention raises questions about how regenerative medicine clinics communicate emerging treatments to prospective patients. Under Federal Trade Commission standards, health-related advertising must be truthful and supported by adequate scientific evidence. Patient testimonials and individual treatment experiences do not independently establish that a product produces the advertised medical benefits.

For patients considering expensive experimental or emerging treatments, the distinction between promising research and established clinical evidence can be significant. Promotional claims may influence medical decisions and financial commitments, making transparency particularly important. If you have any questions about the treatment you received, call us now.

The Lyon Firm's consumer protection lawyers investigate potentially deceptive healthcare marketing, including representations involving stem cell treatments and regenerative medicine. Contact the Lyon Firm to discuss concerns about potentially misleading treatment claims and your consumer protection rights.

‍

Contact Us

Request a Free Consultation

Taking the first step doesn’t have to be complicated. In just a few minutes, you can share the basics of your case, and our team will guide you from there:

  • It begins with a few simple questions about your situation.
  • From there, a member of our legal team reviews your case.
  • Together, we’ll chart the path forward, helping you take the next step toward resolution.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.